Qynapse

Executive Summary

Qynapse is a pioneering neuroimaging AI company based in Paris, France, founded in 2014. It leverages advanced machine learning to provide accurate and actionable insights from brain scans, aiming to improve diagnosis and treatment monitoring for neurological conditions. By targeting clinicians, patients, payers, and pharmaceutical partners, Qynapse offers a trusted platform that enhances decision-making in the management of disorders such as multiple sclerosis, Alzheimer's disease, and other neurodegenerative conditions. The company's technology integrates seamlessly into clinical workflows, automating quantitative analysis that traditionally required manual effort, thereby reducing variability and accelerating time to diagnosis. In a rapidly growing digital health and AI-driven diagnostics market, Qynapse is well-positioned to capitalize on the increasing demand for objective, scalable neuroimaging tools. Its value proposition extends beyond clinical settings to support pharmaceutical companies in clinical trial efficiency and payer requirements for evidence-based reimbursements. With a strong emphasis on accuracy and trust, Qynapse addresses critical pain points in neurology, where early and precise diagnosis is paramount. As it continues to develop its product portfolio and seek regulatory approvals, the company stands to capture significant market share in Europe and beyond. The convergence of AI, neuroimaging, and digital health positions Qynapse as a compelling player in the future of neuroscience diagnostics.

Upcoming Catalysts (preview)

• Q4 2026CE Mark Approval for Next-Generation Imaging Platform80% success
• Q2 2027Strategic Partnership with a Top-10 Pharmaceutical Company for Alzheimer's Trial Imaging60% success
• Q3 2026Series B Funding Round to Support U.S. Expansion70% success